S
RAPT

SignatureFD’s RAPT Therapeutics RAPT Stock Holding History

SignatureFD’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4
Closed -$548 – 3244
2023
Q3 		$548 Sell
4
-8
-67% -$1.31K ﹤0.01% 3013
2023
Q2 		$1.72K Buy
12
+8
+200% +$1.25K ﹤0.01% 2853
2023
Q1 		$606 Hold
4
– – ﹤0.01% 3069
2022
Q4 		$653 Hold
4
– – ﹤0.01% 3060
2022
Q3 		$1K Hold
4
– – ﹤0.01% 3014
2022
Q2 		$1K Buy
+4
New +$533 ﹤0.01% 2990
2021
Q4 		– Sell
-4
Closed -$1K – 3234
2021
Q3 		$1K Buy
+4
New +$1.06K ﹤0.01% 2897

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

SignatureFD's RAPT Position: Q4 2023 in Review

SignatureFD sold out of RAPT Therapeutics (RAPT) in Q4 2023, closing a stake of 4 shares — an estimated $548 sold.

SignatureFD first reported a position in RAPT in Q3 2021 and held it in 7 quarters. The position peaked at $1.72K in Q2 2023. 108 funds tracked by Wall St. Rank hold RAPT as of Q4 2023.

  • SignatureFD reported no remaining RAPT Therapeutics position as of Q4 2023 after selling out during the quarter.
  • SignatureFD sold 4 RAPT Therapeutics shares in Q4 2023, an estimated $548.
  • SignatureFD first reported a position in RAPT Therapeutics in Q3 2021 and held it in 7 quarters.
  • SignatureFD's RAPT Therapeutics position peaked at $1.72K in Q2 2023.
  • 108 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q4 2023.

Based on SignatureFD's 13F filing for Q4 2023, filed 1 Feb 2024.